Mirati Therapeutics downgraded by JP Morgan with a new price target
$MRTX
Biotechnology: Pharmaceutical Preparations
Health Care
JP Morgan downgraded Mirati Therapeutics from Overweight to Neutral and set a new price target of $65.00 from $94.00 previously